Forte Biosciences IncNASDAQ:FBRX
- LAST PRICE5.6500
- TODAY'S CHANGE (%)-0.9500 (-14.3939%)
- Bid / Lots5.6500/ 1
- Ask / Lots5.8600/ 1
- Open / Previous Close6.5100 / 6.6000
- Day Range
- 52 Week Range
- Volume18,819
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBRX |
|---|---|---|
| 09:36 ET | 200 | 6.5 |
| 09:57 ET | 2400 | 6.6 |
| 09:59 ET | 300 | 6.47 |
| 10:01 ET | 2300 | 6.4501 |
| 10:10 ET | 100 | 6.37 |
| 10:24 ET | 167 | 6.159376 |
| 10:28 ET | 1200 | 6.1204 |
| 10:30 ET | 1983 | 6 |
| 10:32 ET | 484 | 6 |
| 10:48 ET | 100 | 6 |
| 10:55 ET | 2845 | 5.7 |
| 11:13 ET | 500 | 5.71 |
| 11:18 ET | 300 | 5.8 |
| 11:31 ET | 1500 | 5.71 |
| 11:38 ET | 525 | 5.71 |
| 11:56 ET | 200 | 5.645 |
| 12:03 ET | 100 | 5.65 |
| 12:09 ET | 846 | 5.645 |
| 12:43 ET | 124 | 5.7 |
| 12:45 ET | 280 | 5.65 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Forte Biosciences Inc | 9.6M | -0.3x | --- |
Calidi Biotherapeutics Inc | 9.3M | -0.2x | --- |
BioVie Inc | 9.2M | -0.1x | --- |
Kintara Therapeutics Inc | 9.3M | 0.0x | --- |
NuCana PLC | 6.9M | 0.0x | --- |
Burzynski Research Institute Inc | 9.2M | -4.1x | --- |
Company Information
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Contact Information
- Headquarters
- 3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS, TX, United States 75247
- Phone
- 310-618-6994
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Paul Wagner
- Chief Financial Officer
- Antony Riley
- Independent Director
- Scott Brun
- Independent Director
- Stephen Doberstein
- Independent Director
- Barbara Finck
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.01 |
EPS | $-22.03 |
Book Value | $24.30 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
